Clinical trial
Evaluation of the 25 Centimeter (cm) GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface to Treat de Novo and/or Restenotic Lesions of the Superficial Femoral Artery (SFA)
NCT01263665 is registered in ClinicalTrials.gov with W.L.Gore & Associates as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of the 25 Centimeter (cm) GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface to Treat de Novo and/or Restenotic Lesions of the Superficial Femoral Artery (SFA)
- Lead sponsor
- W.L.Gore & Associates
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- December 31, 2010
- Completion date
- November 30, 2015
- Enrollment
- 71 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.